Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis
Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced they have entered into a collaboration and nonexclusive license agreement to combine Repair’s Cholesterol Degrading Platform (CDP) […]
Repair Biotechnologies Announces Appointment of Noted Cardiologists to Scientific Advisory Board
Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, today announced the appointments of Ronald P. Karlsberg, MD, FACC, MSCCT, FAHA, FACP, and Daniel Karlsberg, MD, FACC, FSCCT to its Scientific Advisory Board (SAB). The SAB comprises experts in cardiology, biochemistry of atherosclerosis, and related aspects of immunology. […]
Repair Biotechnologies Demonstrates Rapid Reversal of Atherosclerosis in Mouse Models
Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com) announced today that its lipid nanoparticle (LNP) / messenger RNA (mRNA) therapy has rapidly reversed the progression of atherosclerosis in mouse models applicable to both the rare genetic condition of familial hypercholesterolemia as well as atherosclerosis in the broader population. Repair Biotechnologies develops gene therapies based on the proprietary Cholesterol Degrading […]
Repair Biotechnologies Raises $2.15M Seed Round to Develop Drugs for Age-Related Diseases
SYRACUSE, N.Y.–Repair Biotechnologies, Inc. announced today $2.15 million in seed venture funding, to accelerate the preclinical development of its pipeline of drugs targeting thymus regeneration, cancer, and atherosclerosis. The $2.15 million in funding was led by Jim Mellon, the billionaire investor and Chairman of Juvenescence Ltd. Also participating in the round are Emerging Longevity Ventures, […]
